Literature DB >> 2280189

Hypersecretion of VLDL, but not HDL, by hepatocytes from the JCR:LA-corpulent rat.

J E Vance1, J C Russell.   

Abstract

The JCR:LA-corpulent male rat, when homozygous for the cp gene (cp/cp) is hyperlipidemic and prone to atherosclerosis. Both male and female cp/cp rats have markedly elevated serum levels of triacylglycerols and phospholipids [Dolphin, P.J. et al. 1987. Biochim. Biophys. Acta. 919: 140-148]. In the present study, monolayer cultures of hepatocytes were prepared from male and female, corpulent and lean, rats. There was a marked hypersecretion of all very low density lipoprotein (VLDL) lipid and apoprotein components from corpulent-derived cells. The increased secretion most likely accounts for the increased levels of VLDL lipids and apoproteins previously observed in serum. In contrast, there was no difference between the corpulent and lean hepatocytes in their secretion of high density lipoprotein (HDL) lipids and apoproteins. The difference in triacylglycerol secretion between the lean and corpulent cells was sustained even when the cells were cultured for 24, 48, and 72 h prior to the experiment, by which time the hormonal differences between the corpulent and lean animals would have been largely eliminated. The magnitude of the difference in triacyglycerol secretion did not diminish with increasing time in culture. The biochemical basis responsible for the hypersecretion of VLDL has not yet been established. However, preliminary results suggest that there is an inherent difference in glycerolipid metabolism in the two types of hepatocytes.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2280189

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  8 in total

1.  A novel complex of arginine-silicate improves micro- and macrovascular function and inhibits glomerular sclerosis in insulin-resistant JCR:LA-cp rats.

Authors:  S D Proctor; S E Kelly; J C Russell
Journal:  Diabetologia       Date:  2005-07-01       Impact factor: 10.122

2.  Improvement of vascular dysfunction and blood lipids of insulin-resistant rats by a marine oil-based phytosterol compound.

Authors:  James C Russell; H Stephen Ewart; Sandra E Kelly; Jaroslav Kralovec; Jeffrey L C Wright; Peter J Dolphin
Journal:  Lipids       Date:  2002-02       Impact factor: 1.880

3.  Increased insulin sensitivity and reduced micro and macro vascular disease induced by 2-deoxy-D-glucose during metabolic syndrome in obese JCR: LA-cp rats.

Authors:  J C Russell; S D Proctor
Journal:  Br J Pharmacol       Date:  2007-03-20       Impact factor: 8.739

4.  Sustained decreases in weight and serum insulin, glucose, triacylglycerol and cholesterol in JCR:LA-corpulent rats treated with D-fenfluramine.

Authors:  D N Brindley; P Hales; A I al-Sieni; J C Russell
Journal:  Br J Pharmacol       Date:  1992-03       Impact factor: 8.739

Review 5.  Cardiovascular disease in the JCR:LA-cp rat.

Authors:  J C Russell; S E Graham; M Richardson
Journal:  Mol Cell Biochem       Date:  1998-11       Impact factor: 3.396

6.  Insulin promotes the biosynthesis and secretion of apolipoprotein B-48 by altering apolipoprotein B mRNA editing.

Authors:  F E Thorngate; R Raghow; H G Wilcox; C S Werner; M Heimberg; M B Elam
Journal:  Proc Natl Acad Sci U S A       Date:  1994-06-07       Impact factor: 11.205

7.  Irbesartan-mediated reduction of renal and cardiac damage in insulin resistant JCR : LA-cp rats.

Authors:  J C Russell; S E Kelly; D F Vine; S D Proctor
Journal:  Br J Pharmacol       Date:  2009-10-08       Impact factor: 8.739

8.  Exposure to a northern contaminant mixture (NCM) alters hepatic energy and lipid metabolism exacerbating hepatic steatosis in obese JCR rats.

Authors:  Ryan J Mailloux; Maria Florian; Qixuan Chen; Jin Yan; Ivan Petrov; Melanie C Coughlan; Mahemuti Laziyan; Don Caldwell; Michelle Lalande; Dominique Patry; Claude Gagnon; Kurtis Sarafin; Jocelyn Truong; Hing Man Chan; Nimal Ratnayake; Nanqin Li; William G Willmore; Xiaolei Jin
Journal:  PLoS One       Date:  2014-09-15       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.